MX2017010628A - Proteinas especificas novedosas para pioverdina y pioquelina. - Google Patents

Proteinas especificas novedosas para pioverdina y pioquelina.

Info

Publication number
MX2017010628A
MX2017010628A MX2017010628A MX2017010628A MX2017010628A MX 2017010628 A MX2017010628 A MX 2017010628A MX 2017010628 A MX2017010628 A MX 2017010628A MX 2017010628 A MX2017010628 A MX 2017010628A MX 2017010628 A MX2017010628 A MX 2017010628A
Authority
MX
Mexico
Prior art keywords
muteins
pyochelin
pyoverdine
present disclosure
compositions
Prior art date
Application number
MX2017010628A
Other languages
English (en)
Inventor
Corvey Carsten
Kruip Jochen
Rey Astrid
Fraisse Laurent
Rothe Christine
Hinner Marlon
Lunde Bradley
Wiedenmann Alexander
Stump Heike
Calandra Bernhard
Karst Nathalie
Mourez Michael
Allersdorfer Andrea
Jensen Kristian
Hülsmeyer Martin
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2017010628A publication Critical patent/MX2017010628A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente descripción proporciona muteínas de hNGAL a las que se une un miembro de la familia de pioverdina o pioquelina y que se pueden usar en diversas aplicaciones incluyendo aplicaciones farmacéuticas, por ejemplo, para inhibir o reducir el crecimiento de P. aeruginosa. La presente descripción también se refiere a métodos para preparar una o más muteínas a las que se une pioverdina o pioquelina descritas en la presente descripción, así como a composiciones que comprenden una o más de dichas muteínas. La presente descripción se refiere además a moléculas de ácido nucleico que codifican dichas muteínas y a métodos para la generación de dichas muteínas y moléculas de ácido nucleico. Además, la solicitud describe usos terapéuticos y/o de diagnóstico de estas muteínas así como composiciones que comprenden o más de dichas muteínas.
MX2017010628A 2015-02-18 2016-02-16 Proteinas especificas novedosas para pioverdina y pioquelina. MX2017010628A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305242 2015-02-18
PCT/EP2016/053226 WO2016131804A1 (en) 2015-02-18 2016-02-16 Novel proteins specific for pyoverdine and pyochelin

Publications (1)

Publication Number Publication Date
MX2017010628A true MX2017010628A (es) 2017-12-07

Family

ID=52595246

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010628A MX2017010628A (es) 2015-02-18 2016-02-16 Proteinas especificas novedosas para pioverdina y pioquelina.

Country Status (28)

Country Link
US (8) US9884898B2 (es)
EP (1) EP3259282A1 (es)
JP (1) JP6843754B2 (es)
KR (1) KR20170116158A (es)
CN (1) CN107660211A (es)
AR (1) AR103714A1 (es)
AU (1) AU2016221816B2 (es)
BR (1) BR112017017530A2 (es)
CA (1) CA2976687A1 (es)
CL (1) CL2017002082A1 (es)
CO (1) CO2017009433A2 (es)
CR (1) CR20170425A (es)
DO (1) DOP2017000191A (es)
EA (1) EA035824B1 (es)
EC (1) ECSP17061751A (es)
GT (1) GT201700184A (es)
HK (1) HK1245293A1 (es)
IL (1) IL254013A0 (es)
MA (1) MA41072A1 (es)
MX (1) MX2017010628A (es)
PE (1) PE20171652A1 (es)
PH (1) PH12017501473A1 (es)
SG (1) SG11201706621SA (es)
TN (1) TN2017000348A1 (es)
TW (1) TW201636364A (es)
UY (1) UY36561A (es)
WO (1) WO2016131804A1 (es)
ZA (1) ZA201705257B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549968B2 (en) 2009-12-07 2017-01-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target
EP3789397B1 (en) 2014-05-22 2023-12-06 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
EP3250586B1 (en) 2015-01-28 2021-10-27 Pieris Pharmaceuticals GmbH Novel proteins specific for angiogenesis
JP6843754B2 (ja) * 2015-02-18 2021-03-17 ピエリス ファーマシューティカルズ ゲーエムベーハー ピオベルジン及びピオケリンに特異的な新規なタンパク質
CN107636014B (zh) 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
WO2016177762A1 (en) 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
EP3298029A1 (en) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
ES2938525T3 (es) 2015-05-18 2023-04-12 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anticanceroso
EP3115371A1 (en) * 2015-07-07 2017-01-11 Sanofi Fusion molecules
US10703810B2 (en) 2015-11-30 2020-07-07 Pieris Australia Pty Ltd. Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CN113226360A (zh) * 2018-07-19 2021-08-06 科罗拉多大学评议会 用于肠杆菌素治疗铁缺乏和相关贫血的新用途的方法、系统和组合物
JP2022526367A (ja) 2019-03-29 2022-05-24 ピエリス ファーマシューティカルズ ゲーエムベーハー リポカリンムテインの吸入投与

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
SI1087778T1 (sl) 1998-06-08 2006-02-28 Hoffmann La Roche Uporaba peg-ifn-alfa in ribavirina za zdravljenje kronicnega hepatitisa c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US20070191272A1 (en) 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
AU2009264214B2 (en) 2008-06-24 2013-06-06 Technische Universitaet Muenchen Muteins of hNGAL and related proteins with affinity for a given target
WO2011149962A1 (en) * 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
EP2920202B1 (en) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
CN103074303A (zh) * 2012-12-27 2013-05-01 中国人民解放军第三军医大学 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用
JP6843754B2 (ja) * 2015-02-18 2021-03-17 ピエリス ファーマシューティカルズ ゲーエムベーハー ピオベルジン及びピオケリンに特異的な新規なタンパク質
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules

Also Published As

Publication number Publication date
HK1245293A1 (zh) 2018-08-24
KR20170116158A (ko) 2017-10-18
GT201700184A (es) 2018-10-24
US20180030101A1 (en) 2018-02-01
CN107660211A (zh) 2018-02-02
US10072056B2 (en) 2018-09-11
PE20171652A1 (es) 2017-11-13
US20180371037A1 (en) 2018-12-27
US9884898B2 (en) 2018-02-06
US20180037618A1 (en) 2018-02-08
US10329334B2 (en) 2019-06-25
EA201791841A1 (ru) 2018-01-31
BR112017017530A2 (pt) 2018-04-17
CR20170425A (es) 2017-11-22
WO2016131804A1 (en) 2016-08-25
US20180346532A1 (en) 2018-12-06
AR103714A1 (es) 2017-05-31
US10065998B2 (en) 2018-09-04
MA41072A1 (fr) 2018-10-31
EA035824B1 (ru) 2020-08-17
CL2017002082A1 (es) 2018-04-27
US10118952B2 (en) 2018-11-06
CO2017009433A2 (es) 2017-11-30
SG11201706621SA (en) 2017-09-28
US20180371038A1 (en) 2018-12-27
TW201636364A (zh) 2016-10-16
ECSP17061751A (es) 2017-10-31
JP6843754B2 (ja) 2021-03-17
CA2976687A1 (en) 2016-08-25
UY36561A (es) 2016-09-30
ZA201705257B (en) 2019-06-26
EP3259282A1 (en) 2017-12-27
IL254013A0 (en) 2017-10-31
TN2017000348A1 (en) 2019-01-16
DOP2017000191A (es) 2017-09-29
US20170267734A1 (en) 2017-09-21
JP2018506979A (ja) 2018-03-15
PH12017501473A1 (en) 2018-01-29
US20180037619A1 (en) 2018-02-08
US20180086799A1 (en) 2018-03-29
AU2016221816A1 (en) 2017-10-12
AU2016221816B2 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
PH12017501583A1 (en) Novel proteins specific for cd137
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
MX2020002869A (es) Compuestos de pirazolopirimidinona y usos de los mismos.
MX2020001513A (es) Agentes de union a clec9a y su uso.
MX2018001567A (es) Novedosos polipeptidos de fusion especificos para lag-3 y pd-1.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
PH12015502553A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
EA201990043A1 (ru) Антибактериальные соединения
WO2016060996A3 (en) Interleukin-15 compositions and uses thereof
MX2021010668A (es) Proteinas de fusion de citoquinas.
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
NZ725781A (en) Pesticidal compositions and related methods
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
EA202090448A1 (ru) Дигидрооксадиазиноны
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
MX2018002514A (es) Citotoxinas modificadas y su uso terapeutico.
PH12018500058A1 (en) Fusion molecules
MX2017001566A (es) Terapias antibioticas peptidicas derivadas del bufalo de agua.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: PIERIS PHARMACEUTICALS GMBH

FG Grant or registration